Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-abelson kinase including the T315i mutant

Journal of Medicinal Chemistry

Volumn 56, Issue 9, 2013, Pages 3531-3545

  Hong, Seunghee ^a   Kim, Jinhee ^a   Yun, Sun Mi ^b   Lee, Hyunseung ^b   Park, Yoonsu ^a   Hong, Soon Sun ^b   Hong, Sungwoo ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXYETHYL) 3 [6 (2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL]UREA; 1 (3 HYDROXYPROPYL) 3 [6 (2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL]UREA; 1 [2 (DIMETHYLAMINO)ETHYL] 3 [6 (2 ETHYLPHENYL)BENZO[D]THIAZOL 2 YL]UREA; 1 [6 (2 ETHOXYPHENYL)BENZO[D]THIAZOL 2 YL) 3 (2 HYDROXYETHYL)UREA; 1 [6 (2 ETHOXYPHENYL)BENZO[D]THIAZOL 2 YL) 3 (2 MORPHOLINOETHYL)UREA; 1 [6 (2 ETHOXYPHENYL)BENZO[D]THIAZOL 2 YL) 3 (3 HYDROXYPROPYL)UREA; 1 [6 (2 ETHOXYPHENYL)BENZO[D]THIAZOL 2 YL) 3 [2 (PIPERAZIN 1 YL)ETHYL]UREA; 1 [6 (2 ETHOXYPHENYL)BENZO[D]THIAZOL 2 YL] 3 ETHYLUREA; 1 [6 (2 ETHYLPHENYL)BENZO[D]THIAZOL 2 YL) 3 (2 MORPHOLINOETHYL)UREA; 1 [6 (2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL) 3 (2 MORPHOLINOETHYL)UREA; 1 [6 (2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL) 3 [2 (4 METHYLPIPERAZIN 1 YL)ETHYL]UREA; 1 [6 (2,4 DIMETHOXYPHENYL)BENZO[D]THIAZOL 2 YL] 3 ETHYLUREA; 1 [6 (4 AMINO 2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL] 3 ETHYLUREA; 1 ETHYL 3 (6 PHENYLBENZO[D]THIAZOL 2 YL)UREA; 1 ETHYL 3 [5 (2 METHOXYPHENYL)THIAZOLO[5,4 B]PYRIDIN 2 YL]UREA; 1 ETHYL 3 [5 METHOXY 6 (2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL]UREA; 1 ETHYL 3 [6 (2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL]UREA; 1 ETHYL 3 [6 (2 PROPOXYPHENYL)BENZO[D]THIAZOL 2 YL]UREA; 1 ETHYL 3 [6 (3 METHOXYPYRIDIN 4 YL)BENZO[D]THIAZOL 2 YL]UREA; 1 ETHYL 3 [6 (4 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL]UREA; 1 ETHYL 3 [6 (PYRIDIN 4 YL)BENZO[D]THIAZOL 2 YL]UREA; 1 ETHYL 3 [6 [2 (TRIFLUOROMETHOXY)PHENYL]BENZO[D]THIAZOL 2 YL]UREA; BCR ABL PROTEIN; BENZOTHIAZOLE; NOCODAZOLE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOTHIAZOLES; CELL LINE; CELL PROLIFERATION; DRUG DESIGN; FUSION PROTEINS, BCR-ABL; MICE; MOLECULAR DOCKING SIMULATION; MUTATION; NOCODAZOLE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84877706127     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301891t     Document Type: Article

References (35)

1. Quintas-Cardama, A.; Cortes, J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia Blood 2009, 113, 1619-1630
2. Faderl, S.; Kantarjian, H. M.; Talpaz, M. Chronic myelogenous leukemia: Update on biology and treatment Oncology (Williston Park, N.Y.) 1999, 13, 169-184
3. Eck, M. J.; Manley, P. W. The interplay of structural information and functional studies in kinase drug design: Insights from BCR-Abl Curr. Opin. Cell Biol. 2009, 21, 288-295
4. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1, 493-503
5. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 2001, 344, 1031-1037
6. O'Hare, T.; Eide, C. A.; Deininger, M. W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 2007, 110, 2242-2249
7. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A. M.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J. Med. Chem. 2004, 47, 6658-6661
8. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brüggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005, 7, 129-141
9. Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity J. Med. Chem. 2001, 44, 3965-3977
10. Manley, P. W.; Cowan-Jacob, S. W.; Mestan, J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia Biochim. Biophys. Acta 2005, 1754, 3-13
11. Jabbour, E.; Cortes, J.; Kantarjian, H. Treatment selection after imatinib resistance in chronic myeloid leukemia Target Oncol. 2009, 4, 3-10
12. Quintas-Cardama, A.; Cortes, J. Therapeutic options against BCR-ABL1 T315I positive chronic myelogenous leukemia Clin. Cancer Res. 2008, 14, 4392-4399
13. Choi, H. G.; Ren, P.; Adrian, F.; Sun, F.; Lee, H. S.; Wang, X.; Ding, Q.; Zhang, G.; Xie, Y.; Zhang, J.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W.; Mestan, J.; Gray, N. S.; Sim, T. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl J. Med. Chem. 2010, 53, 5439-5448
14. Ding, Q.; Zhang, J.; Choi, Y.; Adrian, F. J.; Wojciechowski, A.; Zhang, G.; Che, J.; Bursulaya, B.; Cowan-Jacob, S. W.; Rummel, G.; Sim, T.; Gray, N. S. Expanding the diversity of allosteric Bcr-Abl inhibitors J. Med. Chem. 2010, 53, 6934-6946
15. 315 mutant J. Med. Chem. 2012, 53, 10033-10046
16. Ren, X.; Pan, X.; Zhang, Z.; Wang, D.; Lu, X.; Li, Y.; Wen, D.; Long, H.; Luo, J.; Feng, Y.; Zhuang, X.; Zhang, F.; Liu, J.; Leng, F.; Lang, X.; Bai, Y.; She, M.; Tu, Z.; Pan, J.; Ding, K. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib J. Med. Chem. 2013, 56, 879-894
17. Lu, X. Y.; Cai, Q.; Ding, K. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation Curr. Med. Chem. 2011, 18, 2146-2157
18. Weisberg, E.; Choi, H. G.; Ray, A.; Barrett, R.; Zhang, J.; Sim, T.; Zhou, W.; Seeliger, M.; Cameron, M.; Azam, M.; Fletcher, J. A.; Debiec-Rychter, M.; Mayeda, M.; Moreno, D.; Kung, A. L.; Janne, P. A.; Khosravi-Far, R.; Melo, J. V.; Manley, P. W.; Adamia, S.; Wu, C.; Gray, N.; Griffin, J. D. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants Blood 2010, 115, 4206-4216
19. Modugno, M.; Casale, E.; Soncini, C.; Rosettani, P.; Colombo, R.; Lupi, R.; Rusconi, L.; Fancelli, D.; Carpinelli, P.; Cameron, A. D.; Isacchi, A.; Moll, J. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358 Cancer Res. 2007, 67, 7987-7990
20. Young, M. A.; Shah, N. P.; Chao, L. H.; Seeliger, M.; Milanov, Z. V.; Biggs, W. H.; Treiber, D. K.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J.; Sawyers, C. L.; Kuriyan, J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680 Cancer Res. 2006, 66, 1007-1014
21. During preparation of manuscript, ponatinib was recently approved by the FDA for the treatment of CML patients.
22. O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W. S.; Xu, Q.; Metcalf, C. A.; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W.; Druker, B. J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 2009, 16, 401-412
23. Huang, W. S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(imidazo[1,2-b ]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin- 1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J. Med. Chem. 2010, 53, 4701-4719
24. Eide, C. A.; Adrian, L. T.; Tyner, J. W.; Mac Partlin, M.; Anderson, D. J.; Wise, S. C.; Smith, B. D.; Petillo, P. A.; Flynn, D. L.; Deininger, M. W.; O'Hare, T.; Druker, B. J. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile Cancer Res. 2011, 71, 3189-3195
25. Park, H.; Hong, S.; Hong, S. Nocodazole is a high-affinity ligand for the cancer-related kinases ABL, c-KIT, BRAF, and MEK ChemMedChem 2012, 7, 53-56
26. De Brabander, M. J.; Van de Veire, R. M.; Aerts, F. E.; Borgers, M.; Janssen, P. A. The effects of methyl (5-(2-thienylcarbonyl)-1 H-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro Cancer Res. 1976, 36, 905-916
27. Drumma, J. E.; Deiningera, D. D.; Tirana, A. L.; Wanga, T.; Grillota, A.-L.; Liaoa, Y.; Ronkina, S. M.; Stamosa, D. P.; Tanga, Q.; Tiana, S.-K.; Oliver-Shafferb, P. Facile preparation of fused ring azolylureas Tetrahedron Lett. 2007, 48, 5535-5538
28. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y. J.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y. F.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res. 2006, 66, 5790-5797
29. Zhou, T.; Parillon, L.; Li, F.; Wang, Y.; Keats, J.; Lamore, S.; Xu, Q.; Shakespeare, W.; Dalgarno, D.; Zhu, X. Crystal structure of the T315I mutant of AbI kinase Chem. Biol. Drug Des. 2007, 70, 171-181
30. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 2000, 289, 1938-1942
31. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res. 2006, 66, 5790-5797
32. Park, H.; Chi, O.; Kim, J.; Hong, S. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure J. Chem. Inf. Model. 2011, 51, 2986-2993
33. Oda, T.; Heaney, C.; Hagopian, J. R.; Okuda, K.; Griffin, J. D.; Druker, B. J. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia J. Biol. Chem. 1994, 269, 22925-22928
34. Shuai, K.; Halpern, J.; ten Hoeve, J.; Rao, X.; Sawyers, C. L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia Oncogene 1996, 13, 247-254
35. La Rosée, P.; Corbin, A. S.; Stoffregen, E. P.; Deininger, M. W.; Druker, B. J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) Cancer Res. 2002, 62, 7149-7153